What is Type 4 Hypersensitivity Reaction (HSR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Type 4 Hypersensitivity Reaction (HSR)

Type 4 HSR is a delayed, T-cell mediated immune response that occurs hours to days after antigen exposure, characterized by lymphocyte activation rather than antibody production. 1, 2

Mechanism and Timing

  • Type 4 reactions are T-cell dependent mechanisms that develop more than 1 hour after drug administration, but commonly manifest after many days of exposure 3
  • Unlike immediate reactions (Type 1), these are not mediated by IgE antibodies but rather by activated T lymphocytes (both CD4+ and CD8+ cells) 1, 4
  • The typical timeframe is 24-72 hours after antigen exposure, though reactions can occur at any time during treatment 5

Clinical Manifestations

Type 4 HSR presents with diverse cutaneous and systemic manifestations 1, 2:

  • Maculopapular exanthema (drug rashes)
  • Allergic contact dermatitis (e.g., nickel allergy, dental materials) 4, 5
  • Severe cutaneous adverse reactions (SCARs) including:
    • Stevens-Johnson syndrome (SJS)
    • Toxic epidermal necrolysis (TEN)
    • Drug reaction with eosinophilia and systemic symptoms (DRESS)
    • Acute generalized exanthematous pustulosis (AGEP) 1
  • Psoriasis 1
  • Erythema multiforme 1

Subtypes of Type 4 HSR

Modern classification divides Type 4 reactions into four subtypes based on the dominant T-cell population and cytokine profile 6, 7:

  • Type IVa: CD4+ Th1-mediated with interferon-gamma, causing contact dermatitis and granuloma formation 6, 7
  • Type IVb: CD4+ Th2-mediated with IL-4, IL-5, IL-13, causing maculopapular exanthema with eosinophilia and chronic asthma 6, 7
  • Type IVc: CD8+ cytotoxic T-cell mediated with perforin and granzyme B, causing bullous reactions like SJS/TEN 6, 7
  • Type IVd: T-cell driven neutrophilic inflammation with IL-8 and GM-CSF, causing pustular reactions like AGEP 6, 7

Critical Management Distinctions

Type 4 reactions are typically NOT amenable to desensitization, unlike immediate Type 1 reactions 1:

  • Severe T-cell mediated delayed reactions (SJS/TEN, DRESS) are associated with long-lasting memory T-cell responses and typically indicate the drug must be completely avoided 1
  • Immediate discontinuation of the suspected culprit drug is essential 2, 3
  • Treatment includes topical corticosteroids and oral antihistamines for mild-moderate reactions 2, 3
  • Systemic corticosteroids and specialized care are required for severe reactions like SJS/TEN and DRESS 2, 3

Diagnostic Approach

  • Delayed intradermal testing (dIDT) may be useful for certain cutaneous adverse reactions but should be avoided in SJS/TEN where sensitivity is low 1
  • Patch testing is the primary diagnostic tool for contact allergic reactions, identifying allergens such as metals (gold, nickel, mercury, palladium), acrylates, and other haptens 5
  • Complete blood count with differential, liver and kidney function tests, and HLA genotyping for specific drug-gene associations may aid diagnosis 2

Common Pitfalls

  • Do not attempt desensitization for severe cutaneous adverse reactions (SCARs) - these require permanent drug avoidance 1
  • Skin testing for chemotherapeutic agents may not be possible due to skin toxicity of the drugs themselves 1
  • Clinical presentations often represent an overlap of cytokine pathways, with one reaction type dominating the final picture 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis and Management of Drug Hypersensitivity Reactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Drug Hypersensitivity Reactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Allergic Reactions Classification and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Chapter 28: Classification of hypersensitivity reactions.

Allergy and asthma proceedings, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.